{
    "xml": "<topic id=\"PHP1748\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/formoterol-fumarate\" basename=\"formoterol-fumarate\" title=\"FORMOTEROL FUMARATE\">\n<title>FORMOTEROL FUMARATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_722\" namespace=\"/interactions/list-of-drug-interactions/sympathomimetics-beta2/formoterol\">Formoterol</xref>\n</p>\n<data name=\"vtmid\">386171009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_531592176\" title=\"Beta2 agonists (long-acting)\">Beta2 agonists (long-acting)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34629\" title=\"SELECTIVE BETA2 AGONISTS\" namespace=\"/drug-classes/selective-beta2-agonists\">SELECTIVE BETA2 AGONISTS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Eformoterol fumarate</p>\r\n</body>\n<topic id=\"PHP66971\" outputclass=\"indicationsAndDose\" rev=\"1.24\" parent=\"/drugs/formoterol-fumarate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy</p>\n<p outputclass=\"therapeuticIndication\">Nocturnal asthma in patients requiring long-term regular bronchodilator therapy</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy</p>\n<p outputclass=\"therapeuticIndication\">Chronic asthma in patients who regularly use an inhaled corticosteroid</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By inhalation of powder</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 6&#8211;11 years</p>\n<p>12&#8239;micrograms twice daily, a daily dose of 24&#8239;micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>12&#8239;micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24&#8239;micrograms twice daily, a daily dose of 24&#8239;micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>12&#8239;micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24&#8239;micrograms twice daily.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By inhalation of aerosol</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>12&#8239;micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24&#8239;micrograms twice daily, a daily dose of 24&#8239;micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>12&#8239;micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24&#8239;micrograms twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Chronic obstructive pulmonary disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By inhalation of powder</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>12&#8239;micrograms twice daily.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By inhalation of aerosol</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>12&#8239;micrograms twice daily (max. per dose 24&#8239;micrograms), for symptom relief additional doses may be taken to maximum daily dose; maximum 48&#8239;micrograms per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"pharmacokinetics\">\n<title>Pharmacokinetics</title>\n<p>At recommended inhaled doses, the duration of action of formoterol is about 12 hours.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67030\" outputclass=\"importantSafetyInformation\" rev=\"1.11\" parent=\"/drugs/formoterol-fumarate\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">CHM Advice</p>\n<p>To ensure safe use, the CHM has advised that for the management of chronic asthma, long-acting beta<sub>2</sub> agonist (formoterol) should:</p>\n<ul>\n<li>be added only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately;</li>\n<li>not be initiated in patients with rapidly deteriorating asthma;</li>\n<li>be introduced at a low dose and the effect properly monitored before considering dose increase;</li>\n<li>be discontinued in the absence of benefit;</li>\n<li>not be used for the relief of exercise-induced asthma symptoms unless regular inhaled corticosteroids are also used;</li>\n<li>be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66900\" outputclass=\"sideEffects\" rev=\"1.27\" parent=\"/drugs/formoterol-fumarate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">QT-interval prolongation</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dizziness</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">taste disturbances</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66954\" outputclass=\"pregnancy\" parent=\"/drugs/formoterol-fumarate\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Inhaled drugs for asthma can be taken as normal during pregnancy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67111\" outputclass=\"breastFeeding\" parent=\"/drugs/formoterol-fumarate\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Inhaled drugs for asthma can be taken as normal during breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66926\" outputclass=\"patientAndCarerAdvice\" rev=\"1.14\" parent=\"/drugs/formoterol-fumarate\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Advise patients not to exceed prescribed dose, and to follow manufacturer&#8217;s directions; if a previously effective dose of inhaled formoterol fails to provide adequate relief, a doctor&#8217;s advice should be obtained as soon as possible.</p>\n<p>Patients should be advised to report any deterioration in symptoms following initiation of treatment with a long-acting beta<sub>2</sub> agonist.</p>\n<p>Patient or carer should be given advice on how to administer formoterol fumarate inhalers.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1748-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/formoterol-fumarate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76510\" title=\"Pressurised inhalation\" namespace=\"/drugs/formoterol-fumarate/pressurised-inhalation\">Pressurised inhalation</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76505\" title=\"Inhalation powder\" namespace=\"/drugs/formoterol-fumarate/inhalation-powder\">Inhalation powder</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85578\" namespace=\"/drugs/beclometasone-with-formoterol\" title=\"BECLOMETASONE WITH FORMOTEROL\" count=\"1\" rel=\"backlink\">BECLOMETASONE WITH FORMOTEROL</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85580\" namespace=\"/drugs/budesonide-with-formoterol\" title=\"BUDESONIDE WITH FORMOTEROL\" count=\"1\" rel=\"backlink\">BUDESONIDE WITH FORMOTEROL</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85605\" namespace=\"/drugs/fluticasone-with-formoterol\" title=\"FLUTICASONE WITH FORMOTEROL\" count=\"1\" rel=\"backlink\">FLUTICASONE WITH FORMOTEROL</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78360\" namespace=\"/treatment-summaries/asthma\" title=\"Asthma\" count=\"1\" rel=\"backlink\">Asthma</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78465\" namespace=\"/treatment-summaries/bronchodilators\" title=\"Bronchodilators\" count=\"2\" rel=\"backlink\">Bronchodilators</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_722\" namespace=\"/interactions/list-of-drug-interactions/sympathomimetics-beta2/formoterol\" title=\"Formoterol\" count=\"1\" rel=\"link\">Formoterol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34629\" namespace=\"/drug-classes/selective-beta2-agonists\" title=\"SELECTIVE BETA2 AGONISTS\" count=\"1\" rel=\"link\">SELECTIVE BETA2 AGONISTS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76510\" namespace=\"/drugs/formoterol-fumarate/pressurised-inhalation\" title=\"Pressurised inhalation\" count=\"1\" rel=\"link\">Pressurised inhalation</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76505\" namespace=\"/drugs/formoterol-fumarate/inhalation-powder\" title=\"Inhalation powder\" count=\"1\" rel=\"link\">Inhalation powder</xref>\n</links>\n</topic>",
    "id": "PHP1748",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/formoterol-fumarate",
    "basename": "formoterol-fumarate",
    "title": "FORMOTEROL FUMARATE",
    "interactants": [
        {
            "id": "bnf_int_722",
            "label": "Formoterol"
        }
    ],
    "vtmid": "386171009",
    "drugClassification": [
        "Beta2 agonists (long-acting)"
    ],
    "inheritsFromClass": [
        "SELECTIVE BETA2 AGONISTS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Eformoterol fumarate"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy",
                        "html": "Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy"
                    },
                    {
                        "textContent": "Nocturnal asthma in patients requiring long-term regular bronchodilator therapy",
                        "html": "Nocturnal asthma in patients requiring long-term regular bronchodilator therapy"
                    },
                    {
                        "textContent": "Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy",
                        "html": "Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy"
                    },
                    {
                        "textContent": "Chronic asthma in patients who regularly use an inhaled corticosteroid",
                        "html": "Chronic asthma in patients who regularly use an inhaled corticosteroid"
                    }
                ],
                "specificity": {
                    "routes": [
                        "inhalation of aerosol"
                    ],
                    "textContent": "By inhalation of aerosol",
                    "html": "By inhalation of aerosol"
                },
                "child": [
                    {
                        "textContent": "12 micrograms twice daily, a daily dose of 24 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.",
                        "html": "<p>12&#8239;micrograms twice daily, a daily dose of 24&#8239;micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.</p>",
                        "ageGroup": "6&#8211;11 years"
                    },
                    {
                        "textContent": "12 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24 micrograms twice daily, a daily dose of 24 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.",
                        "html": "<p>12&#8239;micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24&#8239;micrograms twice daily, a daily dose of 24&#8239;micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.</p>",
                        "ageGroup": "12&#8211;17 years"
                    },
                    {
                        "textContent": "12 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24 micrograms twice daily, a daily dose of 24 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.",
                        "html": "<p>12&#8239;micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24&#8239;micrograms twice daily, a daily dose of 24&#8239;micrograms of formoterol should be sufficient for the majority of children, particularly for younger age-groups; higher doses should be used rarely, and only when control is not maintained on the lower dose.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "12 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24 micrograms twice daily.",
                        "html": "<p>12&#8239;micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24&#8239;micrograms twice daily.</p>"
                    },
                    {
                        "textContent": "12 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24 micrograms twice daily.",
                        "html": "<p>12&#8239;micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24&#8239;micrograms twice daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Chronic obstructive pulmonary disease",
                        "html": "Chronic obstructive pulmonary disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "inhalation of aerosol"
                    ],
                    "textContent": "By inhalation of aerosol",
                    "html": "By inhalation of aerosol"
                },
                "adult": [
                    {
                        "textContent": "12 micrograms twice daily.",
                        "html": "<p>12&#8239;micrograms twice daily.</p>"
                    },
                    {
                        "textContent": "12 micrograms twice daily (max. per dose 24 micrograms), for symptom relief additional doses may be taken to maximum daily dose; maximum 48 micrograms per day.",
                        "html": "<p>12&#8239;micrograms twice daily (max. per dose 24&#8239;micrograms), for symptom relief additional doses may be taken to maximum daily dose; maximum 48&#8239;micrograms per day.</p>"
                    }
                ]
            }
        ],
        "pharmacokinetics": [
            {
                "type": "pharmacokinetics",
                "title": "Pharmacokinetics",
                "textContent": "At recommended inhaled doses, the duration of action of formoterol is about 12 hours.",
                "html": "<p>At recommended inhaled doses, the duration of action of formoterol is about 12 hours.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "CHM Advice",
                "textContent": "To ensure safe use, the CHM has advised that for the management of chronic asthma, long-acting beta2 agonist (formoterol) should:\n\nbe added only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately; not be initiated in patients with rapidly deteriorating asthma; be introduced at a low dose and the effect properly monitored before considering dose increase; be discontinued in the absence of benefit; not be used for the relief of exercise-induced asthma symptoms unless regular inhaled corticosteroids are also used; be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved.",
                "html": "<p>To ensure safe use, the CHM has advised that for the management of chronic asthma, long-acting beta<sub>2</sub> agonist (formoterol) should:</p><ul>\n<li>be added only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately;</li>\n<li>not be initiated in patients with rapidly deteriorating asthma;</li>\n<li>be introduced at a low dose and the effect properly monitored before considering dose increase;</li>\n<li>be discontinued in the absence of benefit;</li>\n<li>not be used for the relief of exercise-induced asthma symptoms unless regular inhaled corticosteroids are also used;</li>\n<li>be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved.</li>\n</ul>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "QT-interval prolongation",
                        "html": "QT-interval prolongation",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Dizziness",
                        "html": "Dizziness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "taste disturbances",
                        "html": "taste disturbances",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Inhaled drugs for asthma can be taken as normal during pregnancy.",
                "html": "<p>Inhaled drugs for asthma can be taken as normal during pregnancy.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Inhaled drugs for asthma can be taken as normal during breast-feeding.",
                "html": "<p>Inhaled drugs for asthma can be taken as normal during breast-feeding.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Advise patients not to exceed prescribed dose, and to follow manufacturer&#8217;s directions; if a previously effective dose of inhaled formoterol fails to provide adequate relief, a doctor&#8217;s advice should be obtained as soon as possible.\n\nPatients should be advised to report any deterioration in symptoms following initiation of treatment with a long-acting beta2 agonist.\n\nPatient or carer should be given advice on how to administer formoterol fumarate inhalers.",
                "html": "<p>Advise patients not to exceed prescribed dose, and to follow manufacturer&#8217;s directions; if a previously effective dose of inhaled formoterol fails to provide adequate relief, a doctor&#8217;s advice should be obtained as soon as possible.</p><p>Patients should be advised to report any deterioration in symptoms following initiation of treatment with a long-acting beta<sub>2</sub> agonist.</p><p>Patient or carer should be given advice on how to administer formoterol fumarate inhalers.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76510",
                "label": "Pressurised inhalation",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76505",
                "label": "Inhalation powder",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP85578",
                "label": "BECLOMETASONE WITH FORMOTEROL",
                "type": "drug"
            },
            {
                "id": "PHP85580",
                "label": "BUDESONIDE WITH FORMOTEROL",
                "type": "drug"
            },
            {
                "id": "PHP85605",
                "label": "FLUTICASONE WITH FORMOTEROL",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78360",
                "label": "Asthma",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78465",
                "label": "Bronchodilators",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_722",
                "label": "Formoterol",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34629",
                "label": "SELECTIVE BETA2 AGONISTS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76510",
                "label": "Pressurised inhalation",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76505",
                "label": "Inhalation powder",
                "type": "medicinalForm"
            }
        ]
    }
}